| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SKB-518 | SKB518; SKB-518 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Genital Neoplasms, Female; Lung Neoplasms; Neoplasms; Solid tumours | Details |
| Cofetuzumab Pelidotin | PF-06647020; PF-6647020; PTK7-ADC; PF-06523435; PF-7020; hu-24; ABBV-647; Anti-PTK7 ADC; h6M24-vc0101 | Phase 1 Clinical | Abbvie Inc, Stemcentrx Inc | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| 68Ga-Sgc8 | Phase 1 Clinical | The First Affiliated Hospital of Air Force Medical University | Colorectal Neoplasms | Details | |
| PTK7 ADC (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details | |
| KIVU-107 | KIVU-107 | Phase 1 Clinical | Kivu Bioscience Inc | Solid tumours | Details |
| LY-4175408 | LY4175408; LY-4175408 | Phase 1 Clinical | Eli Lilly And Company | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Neoplasm Metastasis; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms | Details |
| IDE-034 | BCG034; IDE034; IDE-034 | Phase 1 Clinical | Colorectal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Solid tumours | Details | |
| DAY-301 | DAY301; DAY-301; MTX-13; CB-002 | Phase 1 Clinical | Shanghai Mycos Biomedicine Co Ltd | Solid tumours | Details |
